A case report and literature review was published on September 12, 2026 in Endocrine Journal. The publication, titled "Tirzepatide for pasireotide-induced hyperglycemia in a GH/TSH-producing pituitary adenoma/PitNET: a case report and literature review," is indexed under PubMed ID 42732962.
The report addresses hyperglycemia associated with pasireotide use in the context of a GH/TSH-producing pituitary adenoma, also referred to as a PitNET. It discusses tirzepatide in relation to managing this reported hyperglycemia.
Pasireotide remains an approved compound. This publication is a case report combined with a literature review, which is a form of medical reporting that details individual patient experiences alongside existing published research on the topic.
No additional details about findings, outcomes, or conclusions have been provided beyond the publication title, journal, and date. Readers interested in learning more about this case report can access it through the listed source.
For further background on pasireotide, including its approved uses and general profile, readers can refer to the compound overview.